Cardiff Oncology Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Contents
Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Royalty revenues | $488 | $386 |
| Costs and expenses: | ||
| Research and development | 32,857 | 27,107 |
| Selling, general and administrative | 13,043 | 13,181 |
| Total operating expenses | 45,900 | 40,288 |
| Loss from operations | (45,412) | (39,902) |
| Other income (expense), net: | ||
| Interest income, net | 4,069 | 1,581 |
| Other expense, net | (98) | (383) |
| Total other income, net | 3,971 | 1,198 |
| Net loss | (41,441) | (38,704) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (24) | (24) |
| Net loss attributable to common stockholders | $(41,465) | $(38,728) |
| Net loss per common share — basic and diluted | $(0.93) | $(0.89) |
| Weighted-average shares outstanding — basic and diluted | 44,677 | 43,600 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.